Extract
We thank S. Suissa and D. Assayag, as well as J. Borchardt, for their interest in our study and for giving us the opportunity to respond to their comments regarding the potential impact of immortal time bias and lead time bias on the observed difference between idiopathic pulmonary fibrosis (IPF) patients treated with or without antifibrotic drugs under real-life conditions. As a key finding of the INSIGHTS-IPF Registry follow-up analysis, we had reported that survival was significantly higher in IPF patients receiving antifibrotic therapy when compared with propensity-matched IPF patients not receiving such drugs [1].
Abstract
Survival differences favouring antifibrotic therapy from INSIGHTS-IPF registry data are not compromised by immortal and lead time biases https://bit.ly/3tDpk1S
Footnotes
Conflict of Interest: J. Behr reports grants and personal fees from Boehringer Ingelheim, personal fees from Actelion, Roche, Galapagos, Promedior, BMS and MSD, during the conduct of the study.
Conflict of Interest: D. Pittrow reports personal fees from Actelion, Bayer, Boehringer Ingelheim, Sanofi, Biogen, Shield and MSD, outside the submitted work.
Conflict of Interest: J. Klotsche has nothing to disclose.
- Received January 29, 2021.
- Accepted February 1, 2021.
- Copyright ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org